SCHEMBL4140728

SCHEMBL4140728

Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(NC3=NC(=O)C(=Cc4ccc(-n5cnnn5)cc4OCc4ccccc4)S3)cc2)cc1.[NaH]

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.40
PTGER1 P34995 1/20 0.37
ALDH1A1 P00352 2/20 0.36
EGFR P00533 5/20 0.35
LMNA P02545 2/20 0.34
PKM P14618 1/20 0.34
PPARG P37231 1/20 0.34
ERBB2 P04626 4/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140726 1.00 PTPN1 (0.40) PTPN1PTGER1ALDH1A1EGFRLMNA
SCHEMBL4133898 0.88 ALDH1A1 (0.40) ALDH1A1EGFRLMNAPKMMAPT
SCHEMBL4133903 0.88 ALDH1A1 (0.40) ALDH1A1EGFRLMNAPKMMAPT
SCHEMBL4131998 0.87 LMNA (0.45) PTPN1ALDH1A1EGFRLMNAPPARG
SCHEMBL4131993 0.87 LMNA (0.45) PTPN1ALDH1A1EGFRLMNAPPARG
SCHEMBL4133773 0.85 EGFR (0.41) PTPN1ALDH1A1EGFRLMNAPPARG
SCHEMBL4133774 0.85 EGFR (0.41) PTPN1ALDH1A1EGFRLMNAPPARG
SCHEMBL4128343 0.85 EGFR (0.42) PTPN1ALDH1A1EGFRLMNAPPARG
SCHEMBL4128340 0.85 EGFR (0.42) PTPN1ALDH1A1EGFRLMNAPPARG
SCHEMBL4133775 0.85 EGFR (0.42) PTPN1ALDH1A1EGFRLMNAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTPN1 7/4885PTGER1 1399/4885ALDH1A1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.